<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307241</url>
  </required_header>
  <id_info>
    <org_study_id>010/020/ICI</org_study_id>
    <nct_id>NCT01307241</nct_id>
  </id_info>
  <brief_title>RFC and MTHFR SNPs &amp; hENT1- dCK Expression as Prognostic Factors in ALL &amp; hENT1- dCK Expression as Prognostic Factors in AML</brief_title>
  <official_title>Evaluation of RFC Transporter &amp; MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Cancerología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Cancerología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Results of actual treatment in ALL are not optimal. New prognostic factors, which may
      determine clinical &amp; molecular response are required. Hyper-CVAD is an internationally
      accepted schema for such patients. The objective of this pilot study is to evaluate
      polymorphisms regarding RFC (reduced folate carrier) and MTHFR enzyme, which may affect the
      function of these proteins, and therefore the intracellular bioavailability of methotrexate.
      Also, the expression levels of hENT1 and dCK will be evaluated, since such genes codify for
      citarabine intracellular transport and activation, respectively. Clinical characteristics
      will be tabulated and analyzed for responders &amp; non-responders patients. Uni- &amp; multivariate
      analysis will be done to evaluate factors influencing on response and survival.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate clinical response</measure>
    <time_frame>December 2012</time_frame>
    <description>To evaluate clinical response after ending Hyper-CVAD schema for ALL patients. To evaluate clinical response &amp; DFS in relation with hENT1 &amp; dCK expression levels in AML patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical responses in relation with SNP's or gene expression</measure>
    <time_frame>clinical response.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Lymphoblastic Leukemia.</condition>
  <condition>Acute Myeloblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>one cohort</arm_group_label>
    <description>Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute lymphoblastic leukemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: older than 15 years.

          -  Male, female.

          -  Normal renal &amp; liver functions.

          -  Without previous treatment.

          -  Candidate to be treated with hyperCVAD Schema (ALL patients).

          -  Candidate to receive induction remission with cytarabine (AML patients)

        Exclusion Criteria:

          -  Patients not candidate to receive methotrexate or cytarabine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>myrna candelaria, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerología Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico city</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Cancerología</investigator_affiliation>
    <investigator_full_name>DR. MYRNA CANDELARIA</investigator_full_name>
    <investigator_title>Clinical researcher.</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>prognostic factor</keyword>
  <keyword>pharmacogenetics.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

